Israeli cybersecurity startup Dux, has raised $9 million in a Seed funding round, led by Redpoint, TLV Partners, and Maple Capital, with participation from senior cybersecurity executives associated with CrowdStrike, Okta, and Armis.
The company wants to address the growing gap between how fast cyber vulnerabilities are exploited and how slowly organizations are able to respond in real-world conditions. Reports show that attackers are moving much faster than before, leaving security teams with very little time to act.
According to Mandiant, the average time between a vulnerability being disclosed and exploited has dropped sharply from 32 days to just five days over the past two years. More recently, Anthropic reported the first known real-world cyber-espionage campaign where attackers used agentic AI not only to support human hackers, but to carry out attacks on its own.
In this context, Dux believes that traditional vulnerability management approaches are no longer effective. Models that rely on occasional scans, long remediation timelines and manual risk prioritization cannot keep up with the speed of modern cyber threats.
“Defenders need rapid insight into what’s actually exploitable and the means to reduce those exposures effectively, at the pace modern attacks demand,” said Latovitz, the company’s co-founder and CEO.
To address this, the company has developed an agentic exposure management platform that focuses on identifying what vulnerabilities are truly exploitable within a specific environment and determining the fastest ways to reduce risk.
Dux was founded by Or Latovitz, Amit Nir, and Nadav Geva, all graduates of the IDF’s elite Talpiot program. The founders bring experience from large-scale national cyber and AI projects that were deployed in real-world operations and received multiple national innovation awards.
According to the announcement, the company is already working with and supporting several major U.S. enterprises.
Read More- Allink Biotherapeutics Raises $47M in Series A Extension to Advance Clinical Programs
